Adam Grossman

Dr. Adam Grossman is Praedicat's Vice President of Modeling, Senior Scientist and one of Praedicat's co-founders. Adam works on the modeling team to create and implement Praedicat's risk models. Previously, Adam was an Analyst in the Emerging Risk Solutions group at RMS where he was a core member of the liability catastrophe research and development team that formed the foundation for Praedicat. Adam received his B.A.Sc. in Engineering Science from the University of Toronto, after developing flight training simulators at Defense R&D Canada. He then went on to earn his M.S. and Ph.D. in Bioengineering from Stanford University.

NTP prepares to classify antimony trioxide as a carcinogen

NTP prepares to classify antimony trioxide as a carcinogen 150 150 Adam Grossman

The U.S. National Toxicology Program (NTP) recently completed its draft evaluation of antimony trioxide as a human carcinogen. While the draft is still open for peer review and comment, the…

read more

Generic Drugs, Federal Preemption, and FDA Rulemaking

Generic Drugs, Federal Preemption, and FDA Rulemaking 150 150 Adam Grossman

Praedicat’s new modeling capabilities in the pharmaceutical space present both opportunities for modeling and challenges arising in the ever-changing landscape of federal pharmaceutical law and regulation.  To illustrate how we…

read more